FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097125512> ?p ?o ?g. }

• W2097125512 endingPage "159" @default.
• W2097125512 startingPage "158" @default.
• W2097125512 abstract "OnabotulinumtoxinA (BoNT-ONA) is approved in approximately 75 countries worldwide. The indication for its use ranges from treatment of frown lines between the brows, severe axillary hyperhidrosis, cervical dystonia, chronic migraine, upper limb spasticity, and blepharospasm to strabismus. And the success story continues. BoNT-ONA was recently approved for the treatment of neurogenic bladder overactivity due to multiple sclerosis (MS) and spinal cord injury. The approval for refractory idiopathic overactive bladder (OAB) is expected soon. Since the first publication showing the beneficial effects of BoNT-ONA in the treatment of idiopathic bladder overactivity, only a few years have passed. Today BoNT-ONA is widely used off-label as a second-line treatment in this patient cohort, even though BoNT-ONA is still not approved. Why? BoNT-ONA has been shown to be effective for neurogenic detrusor activity and also for nonneurogenic bladder overactivity, and severe complications are rare [1–6] .T he main complications in patients with idiopathic OAB include an increase in postvoid residual urine, urinary tract infections, and temporary hematuria [2,7]. Based on the observation that the effect of BoNT-ONA decreases over months, it is now widely recognised that repeated injections are also effective. The symptomatic improvement is maintained after repeated injections [8,9], and injections can be performed using local anesthesia [10]. In addition, the only approved second-line therapy for refractory idiopathic OAB is sacral neuromodulation, a much more complex treatment; other options such as bladder augmentation and bladder catheterization remain unattractive. Furthermore, treatment with BoNT-ONA significantly improves health-related quality of life (HRQoL) in neurogenic and nonneurogenic patients. In 2007, Schurch and colleagues showed that treatment with BoNT-ONA improves HRQoL in patients with neurogenic urinary incontinence [11]. When comparing patients with neurogenic and nonneurogenic bladder overactivity, improvement in HRQoL is greater in neurogenic patients after the first injection. However, after the second injection, improvements in HRQoL score are similar between the groups [12]." @default.
• W2097125512 created "2016-06-24" @default.
• W2097125512 creator A5010409135 @default.
• W2097125512 creator A5035196166 @default.
• W2097125512 date "2012-07-01" @default.
• W2097125512 modified "2023-10-17" @default.
• W2097125512 title "Onabotulinumtoxin A for Idiopathic Overactive Bladder: Raising the Bar" @default.
• W2097125512 cites W14113313 @default.
• W2097125512 cites W1556403338 @default.
• W2097125512 cites W1578011271 @default.
• W2097125512 cites W1989319717 @default.
• W2097125512 cites W1991893845 @default.
• W2097125512 cites W1994178716 @default.
• W2097125512 cites W2013407887 @default.
• W2097125512 cites W2017101410 @default.
• W2097125512 cites W2017208817 @default.
• W2097125512 cites W2019473981 @default.
• W2097125512 cites W2021257414 @default.
• W2097125512 cites W2026548789 @default.
• W2097125512 cites W2034469261 @default.
• W2097125512 cites W2046590607 @default.
• W2097125512 cites W2088618615 @default.
• W2097125512 cites W2088773242 @default.
• W2097125512 cites W2118414104 @default.
• W2097125512 cites W2157993246 @default.
• W2097125512 cites W2227571051 @default.
• W2097125512 doi "https://doi.org/10.1016/j.eururo.2012.04.033" @default.
• W2097125512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22537795" @default.
• W2097125512 hasPublicationYear "2012" @default.
• W2097125512 type Work @default.
• W2097125512 sameAs 2097125512 @default.
• W2097125512 citedByCount "0" @default.
• W2097125512 crossrefType "journal-article" @default.
• W2097125512 hasAuthorship W2097125512A5010409135 @default.
• W2097125512 hasAuthorship W2097125512A5035196166 @default.
• W2097125512 hasConcept C126894567 @default.
• W2097125512 hasConcept C142724271 @default.
• W2097125512 hasConcept C204787440 @default.
• W2097125512 hasConcept C2524010 @default.
• W2097125512 hasConcept C2778941218 @default.
• W2097125512 hasConcept C2779762690 @default.
• W2097125512 hasConcept C2780589192 @default.
• W2097125512 hasConcept C33923547 @default.
• W2097125512 hasConcept C71924100 @default.
• W2097125512 hasConceptScore W2097125512C126894567 @default.
• W2097125512 hasConceptScore W2097125512C142724271 @default.
• W2097125512 hasConceptScore W2097125512C204787440 @default.
• W2097125512 hasConceptScore W2097125512C2524010 @default.
• W2097125512 hasConceptScore W2097125512C2778941218 @default.
• W2097125512 hasConceptScore W2097125512C2779762690 @default.
• W2097125512 hasConceptScore W2097125512C2780589192 @default.
• W2097125512 hasConceptScore W2097125512C33923547 @default.
• W2097125512 hasConceptScore W2097125512C71924100 @default.
• W2097125512 hasIssue "1" @default.
• W2097125512 hasLocation W20971255121 @default.
• W2097125512 hasLocation W20971255122 @default.
• W2097125512 hasOpenAccess W2097125512 @default.
• W2097125512 hasPrimaryLocation W20971255121 @default.
• W2097125512 hasRelatedWork W1968373669 @default.
• W2097125512 hasRelatedWork W1974959567 @default.
• W2097125512 hasRelatedWork W1982172676 @default.
• W2097125512 hasRelatedWork W2018940414 @default.
• W2097125512 hasRelatedWork W2031978047 @default.
• W2097125512 hasRelatedWork W2716113618 @default.
• W2097125512 hasRelatedWork W2897283612 @default.
• W2097125512 hasRelatedWork W2919885264 @default.
• W2097125512 hasRelatedWork W4224326608 @default.
• W2097125512 hasRelatedWork W69721835 @default.
• W2097125512 hasVolume "62" @default.
• W2097125512 isParatext "false" @default.
• W2097125512 isRetracted "false" @default.
• W2097125512 magId "2097125512" @default.
• W2097125512 workType "article" @default.